Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate
|ClinicalTrials.gov Identifier: NCT00043732|
Recruitment Status : Completed
First Posted : August 14, 2002
Last Update Posted : April 27, 2010
|Condition or disease||Intervention/treatment||Phase|
|Rheumatoid Arthritis||Drug: SCIO-469||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of SCIO-469 in Patients in Active Rheumatoid Arthritis Receiving Methotrexate|
|Actual Study Completion Date :||September 2003|
- Assess the safety and tolerability of multiple oral doses of SCIO-469 in patients with active rheumatoid arthritis (RA) who were also receiving stable doses of methotrexate (MTX).
- To assess the efficacy of multiple oral doses of SCIO-469 using the American College of Rheumatology (ACR) response criteria. To determine the PK of multiple oral doses of SCIO-469 in patients with active RA who are also receiving MTX.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00043732
|Study Director:||Scios, Inc. Clinical Trial||Scios, Inc.|